Research Analysts’ Recent Ratings Changes for Septerna (SEPN)

Several brokerages have updated their recommendations and price targets on shares of Septerna (NASDAQ: SEPN) in the last few weeks:

• 8/19/2026 – Septerna had its price target raised by JPMorgan Chase & Co. from $38.00 to $48.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Septerna had its price target raised by JonesTrading from $43.00 to $62.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Septerna had its price target raised by Wells Fargo & Company from $48.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Septerna had its price target raised by HC Wainwright from $40.00 to $60.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Septerna had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $49.00 price target on the stock.
• 8/11/2026 – Septerna was given a new $49.00 price target by Stifel Nicolaus.
• 8/11/2026 – Septerna had its price target raised by Guggenheim from $45.00 to $51.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Septerna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/1/2026 – Septerna had its price target lowered by Guggenheim from $52.00 to $45.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Septerna had its price target raised by Truist Financial Corporation from $35.00 to $43.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Septerna had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.

Insider Activity

In other news, insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. This trade represents a 73.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Daniel D. Long sold 3,334 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,323,321.64. The trade was a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,030 shares of company stock worth $2,329,666 over the last three months. Insiders own 5.80% of the company’s stock.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.